Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
65 Results for "
LDL-R
" in MedChemExpress (MCE) Product Catalog:
Products (65)
65 Results for "LDL-R" in MCE Product Catalog:
Cat. No.: HY-W423578
CAS No.: 6656-19-5
Target:
Research Areas:
LDLR regulator-1 (Compound 7b) is a regulator of the low-density lipoprotein receptor (LDLR), capable of increasing the mRNA expression of LDLR .
Cat. No.: HY-P11071
Research Areas:
Cat. No.: HY-149310
CAS No.: 2743448-32-8
Target:
Research Areas:
Dim16 is a dual PCSK9 inhibitor and HMG-CoAR inhibitor, with an IC50 of 0.8 nM against human PCSK9 and an IC50 of 146.8 μM against HMG-CoAR. Dim16 disrupts the PCSK9-LDLR protein-protein interaction, inhibits the catalytic activity of HMG-CoAR, enhances cellular uptake of extracellular LDL, and suppresses PCSK9-induced platelet aggregation. Dim16 can be used in research related to hypercholesterolemia .
Cat. No.: HY-148626
Target:
Research Areas:
CVI-LM001 is an inhibitor PCSK 9. CVI-LM001 inhibits the interaction of PCSK9 with low-density lipoprotein receptor (LDLR), regulates the level of low-density lipoprotein cholesterol (LDL-C) in the blood, and exhibits lipid-lowering efficacy .
Cat. No.: HY-159595
CAS No.: 1233353-86-0
Research Areas:
PCSK9-IN-29 is a lipid-lowering agent. PCSK9-IN-29 can increase low-density lipoprotein receptor (LDLR) protein expression and decrease PCSK9 protein expression in hepG2 cells. PCSK9-IN-29 can reduce the levels of serum LDL-C, TC, and liver enzyme ALT in crab eating macaques fed a high-fat diet, lower body weight and fat, and increase bone mineral content. PCSK9-IN-29 can be used for research on non-alcoholic fatty liver disease and obesity .
Cat. No.: HY-125916
CAS No.: 58523-30-1
Target:
Cat. No.: HY-P10697
Target:
Research Areas:
Cat. No.: HY-160036
CAS No.: 2794203-47-5
Target:
Research Areas:
PCSK9-IN-22 (compound 29) is an orally active inhibitor of PCSK9. PCSK9-IN-22 inhibits the interaction of the protein with LDLR in vivo .
Cat. No.: HY-161435
Target:
Research Areas:
PCSK9-IN-27 (Compound 108) is a PCSK9 inhibitor (IC50: 3.4 nM). PCSK9-IN-27 reduces LDLR degradation and increases LDL-C uptake .
Cat. No.: HY-161941
CAS No.: 2043947-71-1
Research Areas:
MeIm (compound 7) is a high-affinity PCSK9 targeting peptide mimetic with cholesterol-lowering activity. MeIm increases cellular uptake of LDL (EC50=6.04 μM) by inhibiting the binding of PCSK9 to LDLR (IC50=11.2 μM). MeIm can be used in the study of cardiovascular diseases .
Cat. No.: HY-P10698
CAS No.: 1801681-81-1
Target:
Research Areas:
Cat. No.: HY-N0466R
CAS No.: 58543-16-1
Cat. No.: HY-RS07575
Target:
Research Areas:
LDLR Human Pre-designed siRNA Set A contains three designed siRNAs for LDLR gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-147279
CAS No.: 2643306-81-2
Milpocitide is a low-density lipoprotein receptor (human LDL receptor, LDLR), (293-333)-peptide fragment (EGF-like domain 1) .
Cat. No.: HY-155415
CAS No.: 2929219-77-0
Target:
Research Areas:
PCSK9-IN-20 (Compound 3i) is a PCSK9 inhibitor with an IC50 of 3.96 µM. PCSK9-IN-20 decreases PCSK9 and increases LDLR protein expression in vitro .
Cat. No.: HY-161938
CAS No.: 1565828-01-4
Research Areas:
BRD8518 is a PCSK9 inhibitor (EC50=0.23 μM). BRD8518 lowers blood lipids by upregulating LDLR expression and stimulating LDL uptake. BRD8518 can be used in the study of cardiovascular diseases .
Cat. No.: HY-149429
CAS No.: 928023-21-6
Target:
Research Areas:
PPARδ agonist 9 (compound 21) is a PPARδ agonist (EC50: 3.6 nM). PPARδ agonist 9 has in vivo efficacy, reducing serum levels of MCP-1 in mice and significantly inhibiting atherosclerosis progression in the LDLr-KO model (inhibition rate: 50-60%) .
Cat. No.: HY-161940
Target:
Research Areas:
PCSK9-IN-30 (Compound 3f) is a PCSK9 inhibitor. PCSK9-IN-30 interacts with a cryptic binding groove of PCSK9, inhibiting the binding of PCSK9 to the low-density lipoprotein receptor (LDLR) (IC50 = 537 nM), restoring the uptake of low-density lipoprotein (LDL) by liver cells, and ultimately reducing plasma cholesterol levels. PCSK9-IN-30 exhibits good bioavailability in mice and can be used for research in the field of cardiovascular diseases .
Cat. No.: HY-RS16615
Target:
Research Areas:
Ldlr Mouse Pre-designed siRNA Set A contains three designed siRNAs for Ldlr gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-RS23050
Target:
Research Areas:
Ldlr Rat Pre-designed siRNA Set A contains three designed siRNAs for Ldlr gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
